Cyltezo(Cf) Pen (Adalimumab-Adbm) Patent Expiration, LOE Window & CMS Spending

Cyltezo(Cf) Pen (Adalimumab-Adbm) by Boehringer Ingelheim: Biologic BLA (Purple Book Regime), 0 AB generics, $53.9M 2024 CMS Part D & Medicaid spend, and $19,729 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBoehringer Ingelheim
FDA Application & PathwayB761058 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$53.9M
2024 Medicare Part D Spend$52.7M
2024 Medicaid Spend$1.2M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($19,729 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.